Literature DB >> 8208966

Female pelvis: impact of MR imaging on treatment decisions and net cost analysis.

L B Schwartz1, E Panageas, R Lange, J Rizzo, F Comite, S McCarthy.   

Abstract

PURPOSE: To determine the impact of gynecologic magnetic resonance (MR) imaging on treatment decisions and net cost.
MATERIALS AND METHODS: Sixty-nine consecutive women were referred for 70 pelvic MR imaging examinations. Diagnosis and treatment plans were obtained from referring physicians before and immediately after they were given verbal reports of MR imaging results. Outcome regarding treatment and symptoms was obtained at a mean follow-up of 10.9 months.
RESULTS: Of 49 (71%) patients originally recommended for surgery, 36 (73%) either did not undergo surgery or less invasive surgery was performed. In 58 (84%) patients, the treatment performed was that recommended after performance of MR imaging. Symptoms resolved in 57 (83%) patients. Use of MR imaging resulted in an overall savings of $63 per patient ($1,736 per patient originally recommended for surgery).
CONCLUSION: Use of pelvic MR imaging in diagnosis of some gynecologic diseases may alter treatment, decrease the number of invasive surgical procedures performed, and reduce total health care expenditures.

Entities:  

Mesh:

Year:  1994        PMID: 8208966     DOI: 10.1148/radiology.192.1.8208966

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  3 in total

1.  Simulated impact of pelvic MRI in treatment planning for pediatric adnexal masses.

Authors:  Alessandro Marro; Lisa M Allen; Sari L Kives; Rahim Moineddin; Govind B Chavhan
Journal:  Pediatr Radiol       Date:  2016-04-20

Review 2.  Ovarian cancer: the clinical role of US, CT, and MRI.

Authors:  Kaori Togashi
Journal:  Eur Radiol       Date:  2003-12       Impact factor: 5.315

3.  Magnetic Resonance Imaging Characteristics of Ovarian Clear Cell Carcinoma.

Authors:  Wei Wang; Jianhui Ding; Xiaoli Zhu; Yuan Li; Yajia Gu; Weijun Peng
Journal:  PLoS One       Date:  2015-07-10       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.